Halozyme Therapeutics (HALO) Cash from Financing Activities (2010 - 2026)

Halozyme Therapeutics (HALO) has reported Cash from Financing Activities for 17 consecutive years, with -$1.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 51.43% year-over-year to -$1.6 million; the TTM figure through Mar 2026 stood at -$83.5 million (up 62.35% YoY), while the FY2025 annual figure was -$85.2 million, up 61.08% from the prior year.
• Cash from Financing Activities eased to -$1.6 million in Q1 2026 per HALO's latest filing, from $239.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $367.8 million in Q2 2022 and bottomed at -$299.0 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged -$20.7 million across 5 years, with a median of -$489000.0 in 2024.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 921.81% — and 2023, when it sank 26480.45%.
• Halozyme Therapeutics' Cash from Financing Activities stood at $6.3 million in 2022, then plunged by 4048.81% to -$249.9 million in 2023, then climbed by 1.4% to -$246.4 million in 2024, then jumped by 197.2% to $239.5 million in 2025, then tumbled by 100.67% to -$1.6 million in 2026.
• Business Quant data shows HALO's Cash from Financing Activities at -$1.6 million in Q1 2026, $239.5 million in Q4 2025, and -$22.4 million in Q3 2025.